Expression of Micrornas-106B in Nonsmall Cell Lung Cancer

Yuan Li,Jing Tian,Zi-Jian Guo,Zhu-Bo Zhang,Chang-Yan Xiao,Xiao-Chun Wang
DOI: https://doi.org/10.4103/0973-1482.235344
2018-01-01
Journal of Cancer Research and Therapeutics
Abstract:AIM:To explore the expression of microRNA-106b (miRNA-106b) in nonsmall cell lung cancer (NSCLC).SETTINGS AND DESIGN:miRNAs are short regulatory RNAs that negatively modulate gene expression at the posttranscriptional level, and are deeply involved in the pathogenesis of several types of cancer. miRNA-106b has been shown to play an oncogenic role in tumor progression. The expression of miRNA-106b is detected in this study.SUBJECTS AND METHODS:Quantitative reverse transcription polymerase chain reaction and Northern blotting were used to detect the expression level of miRNA-106b in 200 NSCLC samples.STATISTICAL ANALYSIS USED:All statistical analyses were performed using SPSS 16.0 software. Results were statistically evaluated using the Kruskal-Wallis test and Mann-Whitney U-test. Survival curves were estimated by the Kaplan-Meier method and P < 0.05 was considered to be statistically significant.RESULTS:miRNA-106b expression is increased in NSCLC tissues. Statistical analysis showed that overexpression of miRNA-106b was strongly associated with lymph node metastasis, stage of tumor node metastasis classification, and poor prognosis. Moreover, there was a significant difference in the miRNA-106b expression levels between smoking and nonsmoking patients. Multivariate Cox regression analysis showed that miRNA-106b was an independent prognostic factor for NSCLC patients.CONCLUSIONS:These data suggest that aberrantly expressed miRNA-106b may contribute to the development of NSCLC.
What problem does this paper attempt to address?